The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study (Q38460087)

3 September 2017

title

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study (English)

1 reference

3 September 2017

0 references

14

W Ripley Ballou

1 reference

3 September 2017

4

Opokua Ofori-Anyinam

1 reference

3 September 2017

François Spertini

1

1 reference

3 September 2017

Régine Audran

2

1 reference

3 September 2017

Floriana Lurati

3

1 reference

3 September 2017

Frédéric Zysset

5

1 reference

3 September 2017

Pierre Vandepapelière

6

1 reference

3 September 2017

Philippe Moris

7

1 reference

3 September 2017

Marie-Ange Demoitié

8

1 reference

3 September 2017

Pascal Mettens

9

1 reference

3 September 2017

Carlota Vinals

10

1 reference

3 September 2017

Ilse Vastiau

11

1 reference

3 September 2017

Erik Jongert

12

1 reference

3 September 2017

Joe Cohen

13

1 reference

3 September 2017

language of work or name

1 reference

5 December 2012

1 reference

3 September 2017

1 reference

3 September 2017

volume

93

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

179-188

1 reference

HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

New vaccines for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Tuberculosis vaccine development; from mouse to man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Polyfunctional T cells in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Memory CD4+ T cells induce innate responses independently of pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Circulating cytokine concentrations in tuberculosis and other chronic bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

TNF in host resistance to tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Th2 cytokines in susceptibility to tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2012.10.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2012.10.011

1 reference

3 September 2017

1 reference